NanoViricides, Inc（NNVC）のニュースとイベントNNVCNanoViricides, Inc

NanoViricides Enters Agreement for $3.8M Financing with Institutional Investor

NanoViricides entered into a securities purchase agreement with a single fundamental institutional investor for the purchase and sale of 2,516,339 shares of common stock, together with accompanying warrants to purchase 2,516,339 shares of common stock for gross proceeds of approximately $3.8M in a registered direct offering. The common shares are being sold in combination with an accompanying full warrant. Each whole warrant has an exercise price of $1.75 per share and will expire five and half years from the date of issuance. D. Boral Capital is acting as the exclusive placement agent for the Offering. The closing of the Offering is expected to occur on or about July 27, subject to the satisfaction of customary closing conditions. The Company expects to receive aggregate gross proceeds of ~$3.8M from the Offering, before deducting placement agent fees and other related expenses.

NanoViricides Seeks Approval for Phase II Trial of NV-387

NanoViricides has applied to the regulatory agency, ACOREP, for approval to begin a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for the Current Bundibugyo Ebolavirus in the Democratic Republic of Congo. NanoViricides has retained Om Sai Clinical Research Private Limited, India, as the CRO for this Phase II clinical trial for Ebola in DRC. Om Sai CRO has been instrumental in putting together a team with a renowned Principal Investigator and other renowned experts and with support from a well known University in the Ebola-affected region to lead and execute the clinical trial of NV-387 Oral Gummies as a Treatment for Ebolaviruses in DRC. The Principal Investigator has sent in the application for the clinical trial. Om Sai is also the CRO leading the Company's Phase II clinical trial of NV-387 Oral Gummies as a Treatment for Mpox in DRC.